KaloBios Pharmaceuticals Inc. started an early stage test of a treatment aimed at leukemia.
The South San Francisco business treated the first patient in a Phase I trial of KB004, a monoclonal antibody the company has developed. The drug targets the protein EphA3, which is significant in several types of cancer.
No comments:
Post a Comment